title: Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal model.
abstract: OBJECTIVE
  To investigate the hepato-protective properties and underlying mechanisms of SAMC in a non-alcoholic fatty liver disease (NAFLD) rat model.
  
  
  METHODS
  Female rats were fed with a diet comprising highly unsaturated fat diet (30% fish oil) for 8 weeks to develop NAFLD with or without an intraperitoneal injection of 200 mg/kg SAMC three times per week. After euthanasia, blood and liver samples of rats were collected for histological and biochemical analyses.
  
  
  RESULTS
  Co-treatment of SAMC attenuated NAFLD-induced liver injury, fat accumulation, collagen formation and free fatty acids (FFAs). At the molecular level, SAMC decreased the lipogenesis marker and restored the lipolysis marker. SAMC also reduced the expression levels of pro-fibrogenic factors and diminished liver oxidative stress partly through the inhibition in the activity of cytochrome P450 2E1-dependent pathway. NAFLD-induced inflammation was also partially mitigated by SAMC treatment via reduction in the pro-inflammatory mediators, chemokines and suppressor of cytokine signaling. The protective effect of SAMC is also shown partly through the restoration of altered phosphorylation status of FFAs-dependent MAP kinase pathways and diminished in the nuclear transcription factors (NF-κB and AP-1) activity during NAFLD development.
  
  
  CONCLUSIONS
  SAMC is a novel hepato-protective agent against NAFLD caused by abnormal liver functions. Garlic or garlic derivatives could be considered as a potent food supplement in the prevention of fatty liver disease.
authors.affiliation: Department of Anatomy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L1-41, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, SAR.
authors.forename: Jia
authors.initials: J
authors.lastname: Xiao
authors.forename: Yick Pang
authors.initials: YP
authors.lastname: Ching
authors.forename: Emily C
authors.initials: EC
authors.lastname: Liong
authors.forename: Amin A
authors.initials: AA
authors.lastname: Nanji
authors.forename: Man Lung
authors.initials: ML
authors.lastname: Fung
authors.forename: George L
authors.initials: GL
authors.lastname: Tipoe
mesh_terms: D000818:Animals; D015153:Blotting, Western; D003545:Cysteine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019392:Cytochrome P-450 CYP2E1 / Q000235:genetics / Q000378:metabolism; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005234:Fatty Liver / Q000188:drug therapy*; D005260:Female; D005737:Garlic / Q000737:chemistry*; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D050155:Lipogenesis / Q000187:drug effects; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D020935:MAP Kinase Signaling System / Q000187:drug effects; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D065626:Non-alcoholic Fatty Liver Disease; D018384:Oxidative Stress / Q000187:drug effects; D010766:Phosphorylation; D010936:Plant Extracts / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018808:Transcription Factor AP-1 / Q000235:genetics / Q000378:metabolism
chemical_list: D065691:Cytochrome P-450 CYP2E1 Inhibitors; D016328:NF-kappa B; D010936:Plant Extracts; C086300:S-allylmercaptocysteine; D018808:Transcription Factor AP-1; D019392:Cytochrome P-450 CYP2E1; D003545:Cysteine